AIM: £4.30 (-0.29) | Nasdaq: $28.61 (-0.09)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
Innovation Platform
Overview
R&D Approach
Our Pipeline
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Competitive Advantages
Prescription Drugs
Consumer Health
Main Products
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Financial Results
Overview
Chairman's Statement
Financial Highlights
Financial Reports
SEC Filings
Shareholder Information
Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
AIM Rule 26
Career
Career Opportunities
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
Innovation Platform
Overview
R&D Approach
Our Pipeline
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Competitive Advantages
Prescription Drugs
Consumer Health
Main Products
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Financial Results
Overview
Chairman's Statement
Financial Highlights
Financial Reports
SEC Filings
Shareholder Information
Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
AIM Rule 26
Career
Career Opportunities
CNBC Squawk Box
CEO Christian Hogg discusses savolitinib and fruquintinib progress
Watch Interview
FY2018 Results & Programs Update
Announcement and Presentation webcast
View Event Details
Fruquintinib in JAMA
Full text of FRESCO colorectal cancer trial published
Read Abstract
Royal Society of Medicine
CEO Christian Hogg speaks at
RSM Medical Innovations Summit
Watch Presentation
AstraZeneca & Chi-Med
Harnessing the power of Chinese scientific innovation
Learn More
Latest News
Innovation Platform
|
14 Jun 2019
Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early
Group
|
29 May 2019
Results of Extraordinary General Meeting
Group
|
3 May 2019
Notice of Extraordinary General Meeting and Shareholders' Circular
Group
|
15 Apr 2019
Chi-Med Files Application to List in Hong Kong and Announces Proposed Global Offering
Innovation Platform
|
29 Mar 2019
Chi-Med Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in China
Current Share Price
London AIM:HCM
£4.30
-0.29 | 24 Jun 2019 | 10:05
Nasdaq AIM:HCM
US$28.61
-0.09 | 24 Jun 2019 | 16:00
Note: 1 Nasdaq share = 5 AIM shares
Latest Presentations
31 May 2019
Morgan Stanley Annual China Summit 2019
8 May 2019
J.P. Morgan Global China Summit 2019
11 Mar 2019
2018 Full Year Results
4 Mar 2019
Clin Cancer Res: Surufatinib in advanced, well-differentiated neuroendocrine tumors
Latest Reports
Annual Report 2018 (with Form 20-F)
EN
Interim Report 2018
EN
Annual Report 2017 (with Form 20-F)
EN
Share conversions between AIM & Nasdaq
Mailing list sign-up
Analyst Coverage
Bank of America Merrill Lynch
Canaccord Genuity
Deutsche Bank
Edison
HSBC
Panmure Gordon
Trinity Delta
The leading China-based innovator
Our
Innovation Platform
focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.
Learn More
A powerful commercial network in China
Our
Commercial Platform
manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.
Learn More